BioSpace News Archive

Molecure S.A. a clinical stage biotechnology company developing first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases announces first half results for the period ended 30 June 2023.

Microbix Biosystems Inc. announces that it will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 29 to October 1, 2023.

Labcorp, a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2023 before the market opens on Thursday, October 26, 2023.

Hepion Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase and sale of 980,393 shares of its common stock at a purchase price of $5.10 per share in a registered direct offering priced at-the-market under Nasdaq rules.

DENTSPLY SIRONA Inc. announced that, as part of its planned succession process and consistent with the Company’s Board of Directors’ commitment to periodic Board refreshment in line with its Corporate Governance Guidelines, the Board has appointed Gregory T. Lucier as Chairman of the Board and as a member of the Corporate Governance and Nominating Committee, effective January 1, 2024.

Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29th to 30th, 2023.

September 28, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a third amendment to its February 2021

The U.S. Food and Drug Administration is taking steps to help further accelerate the development of novel drug and biological products for rare diseases.

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin.

AB Science wants to focus the majority of our clinical resources on the development of rare diseases with masitinib, on the development of the microtubule platform with AB8939 and future molecules of the same family due to the very encouraging first results.